For Sanofi, Evidation identified 30,000 individuals with type 2 diabetes, at high-risk for the flu. We nudged this population in a variety of ways to obtain the flu vaccine, resulting in a measurable increase in vaccination rates relative to those we did not engage.
Evidation is working with J&J and Apple to improve diagnosis/treatment rates and outcomes for atrial fibrillation. We identify at-risk individuals, engage through tailored insights, and nudge to contact clinicians to get appropriate care sooner.
Our product is available in these therapeutic areas: cardiovascular, respiratory, autoimmune, central nervous system, and infectious disease. Evidation has joined forces with the American College of Cardiology in heart health, and are investing in research and toolkits to support individuals with a heart failure diagnosis.